Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib with cisplatin and gemcitabine for advanced urothelial cancer
ISRCTN54607216Phase 2Completed
- Sponsor
- Cardiff University
- Start
- Jul 2009
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of sunitinib, cisplatin and gemcitabine in transitional cell carcinoma (TCC), sponsored by Cardiff University. Primary endpoint: Progression-free survival at 6 months. Started Jul 2009; status: completed.
02
Drugs
sunitinibcisplatingemcitabine
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ISRCTN54607216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN54607216.